Applied DNA’s LineaRx ‘ready to support’ reshoring of drug development

Applied DNA Sciences (APDN) has completed a long-term initiative to source critical input materials for its LineaDNA and LineaIVT platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain. “With the completion of our supply chain pivot, the LineaDNA platform is now engineered for speed, scale, and domestic sourcing. Localized production of our DNA template materials and manufacturing enzymes enables us to better position LineaRx as a trusted and reliable manufacturing partner for developing and producing genetic medicines,” stated Clay Shorrock, president of LineaRx. “As the largest PCR-based cell-free DNA producer in the United States and with capabilities further enhanced by the recent launch of GMP manufacturing services, we believe we are well-positioned to support increased domestic development and manufacturing of a wide range of genetic medicines, ranging from mRNA/DNA products to cell and gene therapies.”